Ibex Ltd insiders sell shares worth over $1.18 million

In a recent transaction, insiders at IBEX Ltd (NASDAQ:IBEX ), a company specializing in computer processing and data preparation services, have sold a significant amount of shares. The transactions, which occurred between September 13 and September 17, involved the sale of 60,000 common shares at prices ranging from $19.1125 to $20.156, resulting in a total sale value exceeding $1.18 million.


The sales were conducted under a Rule 10b5-1 trading plan, which was adopted by PineBridge Global Emerging Markets Partners II, L.P. on June 14, 2024. This plan allows company insiders to set up a predetermined schedule for buying and selling securities to avoid accusations of insider trading.


According to the SEC filing, the specific prices for the shares sold varied within the stated range. On September 13, shares were sold at prices between $19.00 and $19.46, and on September 16, the range was between $19.95 and $20.45. The final batch of shares sold on September 17 fetched prices ranging from $19.48 to $20.115. The reporting entities have agreed to provide detailed information regarding the number of shares sold at each separate price within the range upon request.


The reported shares were held directly by PineBridge Global Emerging Markets Partners II, L.P., with the transactions being jointly filed by related entities and individuals, including PineBridge GEM II G.P., L.P., John Leone, Kevin Clowe, and Pierre Mellinger. All parties have disclaimed beneficial ownership of the reported securities, except to the extent of their pecuniary interest.


These transactions reflect changes in the ownership stakes of key insiders and entities associated with IBEX Ltd. Investors often monitor such insider trading activities as they can provide insights into the executives' perspective on the company's current valuation and future prospects.



"In other recent news, IBEX Ltd. reported a transformative year with a record increase in earnings per share (EPS) to $2.10 and a rise in free cash flow to $27 million. Despite a slight annual revenue decrease to $509 million, Q4 revenue indicated a year-over-year increase, signaling a potential return to growth. Looking forward to fiscal year 2025, the company expects revenue between $510 million and $525 million and adjusted EBITDA of $67 million to $69 million. Financial services firm Baird has increased its price target for IBEX shares to $23.00, maintaining an Outperform rating, based on the company's potential for revenue growth and margin expansion driven by artificial intelligence. Similarly, RBC Capital Markets has raised its price target for IBEX from $18 to $20, keeping a Sector Perform rating, following the company's announcement of a return to revenue growth. These recent developments highlight the positive trajectory of IBEX's financial performance and growth prospects.
InvestingPro Insights


While insider selling at IBEX Ltd has captured the attention of market watchers, a closer look at the company through the lens of InvestingPro reveals a nuanced picture. IBEX Ltd, with a current market capitalization of $323.63 million, is trading at a P/E ratio of 10.13, which suggests a potentially undervalued position when juxtaposed against its near-term earnings growth. This is further supported by an adjusted P/E ratio for the last twelve months as of Q4 2024 at 9.28, indicating a slight improvement in valuation over time.


Moreover, IBEX Ltd has demonstrated robust returns, with a 13.75% increase over the last week and an even more impressive 40.62% return over the past year. These figures underscore a trend of positive momentum for the company's stock. Additionally, InvestingPro Tips highlight that the company's management has been actively buying back shares and the firm operates with a moderate level of debt, which could be indicative of a confident outlook by the company's leadership regarding its financial health and future performance.


Investors considering IBEX Ltd may also find solace in the fact that the company's cash flows can sufficiently cover interest payments, and its liquid assets exceed short-term obligations. These metrics point to a stable financial foundation, which could be a reassuring signal amidst the insider sales. It's worth noting that IBEX Ltd does not pay a dividend, which can be an important consideration for income-focused investors.


For those looking to delve deeper into IBEX Ltd's financials and strategic positioning, InvestingPro offers additional insights. There are currently 12 more InvestingPro Tips available, which can provide a more comprehensive understanding of the company's investment potential. Interested readers can explore these tips at https://www.investing.com/pro/IBEX to gain an edge in their investment decision-making process.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Source: Investing.com

Последние публикации
Harris accepts CNN invitation to second debate, urges Trump to join
21.09.2024 - 20:00
Court gives 5 days for X to validate its Brazil legal representative
21.09.2024 - 19:00
Hedge funds well-positioned to navigate market swings, says UBS
21.09.2024 - 18:00
SAIC Volkswagen says adjusting plant base "necessary"
21.09.2024 - 13:00
Selling season, election ahead, but keep an eye on ’25, says Wells Fargo
21.09.2024 - 13:00
Investors should de-risk ahead of US elections, BCA says
21.09.2024 - 13:00
How to play the AI Enterprise Software revolution
21.09.2024 - 12:00
Qualcomm approached Intel about a takeover in recent days, source says
21.09.2024 - 08:00
Eliem therapeutics executive sells over $9,000 in company stock
21.09.2024 - 06:00
Nvidia's principal accounting officer sells shares worth over $520,000
21.09.2024 - 05:00
Mara Holdings CFO sells over $262k in company stock
21.09.2024 - 05:00
Mara Holdings CEO sells shares worth over $430k
21.09.2024 - 05:00
Nvidia CFO Colette Kress sells shares worth over $7.7 million
21.09.2024 - 05:00
X names Brazil legal representative as it fights ban in the country
21.09.2024 - 05:00
Viking therapeutics director sells shares worth over $715,000
21.09.2024 - 05:00

© Analytic DC. All Rights Reserved.

new
Анализ трейдера Анализ трейдера за 20.09.24
Добро пожаловать в чат поддержки!
*
*

Ваш запрос успешно отправлен!
Скоро с вами свяжутся.